Dividend-paying stocks can really boost an individual investor's portfolio. If you're in the market for some no-brainer ...
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...
We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...
2d
Could Pfizer Inc.'s (NYSE:PFE) Weak Financials Mean That The Market Could Correct Its Share Price?
Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...
Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a ...
Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the February 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...
Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback